Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NERV 
Minerva Neurosciences Inc (NERV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NERV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.17% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.11M USD | Price to earnings Ratio 1.46 | 1Y Target Price 5 |
Price to earnings Ratio 1.46 | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta -0.27 | 52 Weeks Range 1.15 - 2.87 | Updated Date 09/17/2025 |
52 Weeks Range 1.15 - 2.87 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.34% | Return on Equity (TTM) -675.09% |
Valuation
Trailing PE 1.46 | Forward PE 11.21 | Enterprise Value -142154 | Price to Sales(TTM) 1.87 |
Enterprise Value -142154 | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 2.6 | Shares Outstanding 6993410 | Shares Floating 5437023 |
Shares Outstanding 6993410 | Shares Floating 5437023 | ||
Percent Insiders 22.25 | Percent Institutions 27.99 |
Upturn AI SWOT
Minerva Neurosciences Inc
Company Overview
History and Background
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. Founded in 2007, the company has focused on innovative therapies for unmet needs in CNS disorders.
Core Business Areas
- Clinical Development: Focuses on the development of new drugs to treat central nervous system (CNS) disorders.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry. The company operates with a functional organizational structure, emphasizing research and development.
Top Products and Market Share
Key Offerings
- Rolipram: A phosphodiesterase-4 (PDE4) inhibitor being developed for the treatment of Major Depressive Disorder (MDD). The competitive landscape includes established antidepressant medications (SSRIs, SNRIs) from companies like Eli Lilly (LLY) and Pfizer (PFE), as well as newer therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the CNS segment, is characterized by high R&D costs, stringent regulatory requirements, and significant market potential.
Positioning
Minerva is a clinical-stage company aiming to address unmet needs in CNS disorders. Its competitive advantage lies in its novel drug candidates.
Total Addressable Market (TAM)
The global market for CNS therapeutics is expected to reach hundreds of billions of dollars. Minerva Neurosciences, given its early-stage pipeline and the uncertainties around FDA approval, has a relatively small percentage of the TAM. Estimates suggest TAM to be over $100 Billion. Minerva would need FDA approval and successful commercialization to attain a greater market share.
Upturn SWOT Analysis
Strengths
- Innovative pipeline
- Experienced management team
- Focus on unmet needs in CNS
Weaknesses
- Limited financial resources
- Reliance on successful clinical trials
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- FDA approval of Rolipram and other candidates
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- Eli Lilly (LLY)
- Pfizer (PFE)
- Johnson & Johnson (JNJ)
Competitive Landscape
Minerva faces intense competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Its success hinges on differentiating its products through clinical efficacy and addressing unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by the progression of clinical trials and successful fundraising.
Future Projections: Future growth depends on the successful development and commercialization of its product candidates, particularly Rolipram.
Recent Initiatives: Focus on advancing clinical trials for Rolipram and other pipeline assets, exploring partnerships and financing options.
Summary
Minerva Neurosciences is a high-risk, high-reward clinical-stage company focused on CNS disorders. Its success depends on positive clinical trial results and regulatory approval. The company's lack of revenue and reliance on financing make it vulnerable, but successful drug development could lead to significant growth. The company has some strengths with novel drugs in development, but needs to raise capital and make sure that its clinical trials are successfull to grow.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Investor Relations
- Third-party Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual risk tolerance and thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Minerva Neurosciences Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2014-07-01 | Executive Chairman & CEO Dr. Remy Luthringer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | |
Full time employees 8 | |||
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.